# CLL-1 CAR-NK Cells for Relapsed/Refractory AML

> **NCT06307054** · PHASE1 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 24 (estimated)

## Conditions studied

- Relapsed Adult AML
- Refractory AML

## Interventions

- **DRUG:** anti-CLL-1 CAR NK cells

## Key facts

- **NCT ID:** NCT06307054
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-03-15
- **Final completion:** 2027-03-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06307054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06307054, "CLL-1 CAR-NK Cells for Relapsed/Refractory AML". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06307054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*